[1] Kyle R A, Rajkumar S V. Multiple myeloma[J]. Blood. 2008, 111(6): 2962-2972.
[2] Koeppen S. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy[J]. Oncol Res Treat. 2014, 37(9): 506-513.
[3] Tenreiro M M, Correia M L, Brito M A. Endothelial progenitor cells in multiple myeloma neovascularization: a brick to the wall[J]. Angiogenesis. 2017, 20(4): 443-462.
[4] Otjacques E, Binsfeld M, Noel A, et al. Biological aspects of angiogenesis in multiple myeloma[J]. Int J Hematol. 2011, 94(6): 505-518.
[5] Podar K, Tai Y T, Davies F E, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration[J]. Blood. 2001, 98(2): 428-435.
[6] Moschetta M, Kawano Y, Sacco A, et al. Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing[J]. Curr Osteoporos Rep. 2017, 15(5): 499-506.
[7] Tkach M, Thery C. Communication by Extracellular Vesicles: Where We Are and Where We Need to Go[J]. Cell. 2016, 164(6): 1226-1232.
[8] Wang J, Faict S, Maes K, et al. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma[J]. Oncotarget. 2016, 7(25): 38927-38945.
[9] Boyiadzis M, Whiteside T L. The emerging roles of tumor-derived exosomes in hematological malignancies[J]. Leukemia. 2017, 31(6): 1259-1268.
[10] Farooqi A A, Desai N N, Qureshi M Z, et al. Exosome biogenesis, bioactivities and functions as new delivery systems of natural compounds[J]. Biotechnol Adv. 2017.
[11] Trajkovic K, Hsu C, Chiantia S, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes[J]. Science. 2008, 319(5867): 1244-1247.
[12] Saddoughi S A, Ogretmen B. Diverse functions of ceramide in cancer cell death and proliferation[J]. Adv Cancer Res. 2013, 117: 37-58.
[13] Galadari S, Rahman A, Pallichankandy S, et al. Tumor suppressive functions of ceramide: evidence and mechanisms[J]. Apoptosis. 2015, 20(5): 689-711.
[14] Dany M, Ogretmen B. Ceramide induced mitophagy and tumor suppression[J]. Biochim Biophys Acta. 2015, 1853(10 Pt B): 2834-2845.
[15] Cheng Q, Li X, Wang Y, et al. The ceramide pathway is involved in the survival, apoptosis and exosome functions of human multiple myeloma cells in vitro[J]. Acta Pharmacol Sin. 2018, 39(4) :561-8
[16] Morad S A, Ryan T E, Neufer P D, et al. Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia[J]. J Lipid Res. 2016, 57(7): 1231-1242.
[17] Kong Y W, Ferland-Mccollough D, Jackson T J, et al. microRNAs in cancer management[J]. Lancet Oncol. 2012, 13(6): e249-e258.
[18] Zhang Y K, Wang H, Leng Y, et al. Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1[J]. Biochem Biophys Res Commun. 2011, 414(1): 233-239.
[19] Li Y, Cai B, Shen L, et al. MiRNA-29b suppresses tumor growth through simultaneously inhibiting angiogenesis and tumorigenesis by targeting Akt3[J]. Cancer Lett. 2017, 397: 111-119.
[20] Cheng Q, Li X, Liu J, et al. Multiple Myeloma-Derived Exosomes Regulate the Functions of Mesenchymal Stem Cells Partially via Modulating miR-21 and miR-146a[J]. Stem Cells Int. 2017, 2017: 9012152.
[21] Yabu T, Tomimoto H, Taguchi Y, et al. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate[J]. Blood. 2005, 106(1): 125-134.
[22] Chen D D, Feng L C, Ye R, et al. [miR-29b Reduces Cisplatin Resistance of Gastric Cancer Cell by Targeting PI3K/Akt Pathway][J]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2015, 37(5): 514-519.
[23] Teng Y, Zhang Y, Qu K, et al. MicroRNA-29B (mir-29b) regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3[J]. Oncotarget. 2015, 6(38): 40799-40814.